81 related articles for article (PubMed ID: 1934965)
1. Donor-specific antibodies. Clinical relevance of antibodies detected in lymphocyte crossmatches.
Braun WE
Clin Lab Med; 1991 Sep; 11(3):571-602. PubMed ID: 1934965
[TBL] [Abstract][Full Text] [Related]
2. IgG donor-specific crossmatches are not associated with graft rejection or poor graft survival after liver transplantation. An assessment by cytotoxicity and flow cytometry.
Donaldson PT; Thomson LJ; Heads A; Underhill JA; Vaughan RW; Rolando N; Williams R
Transplantation; 1995 Nov; 60(9):1016-23. PubMed ID: 7491675
[TBL] [Abstract][Full Text] [Related]
3. Crossmatch procedures used in organ transplantation.
Gebel HM; Lebeck LK
Clin Lab Med; 1991 Sep; 11(3):603-20. PubMed ID: 1934966
[TBL] [Abstract][Full Text] [Related]
4. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
5. [Histocompatibility tests in a transplantation program].
de-Leo-Cervantes C
Rev Invest Clin; 2005; 57(2):142-6. PubMed ID: 16524052
[TBL] [Abstract][Full Text] [Related]
6. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
7. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre.
Muro M; Marin L; Miras M; Moya-Quiles R; Minguela A; Sánchez-Bueno F; Bermejo J; Robles R; Ramírez P; García-Alonso A; Parrilla P; Alvarez-López MR
Transpl Immunol; 2005 Jun; 14(2):91-7. PubMed ID: 15935299
[TBL] [Abstract][Full Text] [Related]
8. Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch.
Mahmoud KM; Ismail AM; Sheashaa HA; Gheith OA; Kamal MM; Ghoneim MA
Exp Clin Transplant; 2009 Jun; 7(2):124-8. PubMed ID: 19715518
[TBL] [Abstract][Full Text] [Related]
9. Aortic valve allograft structural deterioration is associated with a subset of antibodies to human leukocyte antigens.
Dignan R; O'Brien M; Hogan P; Thornton A; Fowler K; Byrne D; Stephens F; Harrocks S
J Heart Valve Dis; 2003 May; 12(3):382-90; discussion 390-1. PubMed ID: 12803340
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants.
Billen EV; Christiaans MH; van den Berg-Loonen EM
Tissue Antigens; 2009 Sep; 74(3):205-12. PubMed ID: 19497037
[TBL] [Abstract][Full Text] [Related]
11. [The prognostic significance of pre-existing lymphocytotoxic antibodies in cadaveric kidney allografts with a negative specific crossmatch].
Kharlamova LA; Zemlianitskaia TL; Makhlin NV; Iankovoĭ
Urol Nefrol (Mosk); 1993; (4):30-2. PubMed ID: 8310563
[TBL] [Abstract][Full Text] [Related]
12. IgM antibodies in renal transplantation.
McCalmon RT; Tardif GN; Sheehan MA; Fitting K; Kortz W; Kam I
Clin Transplant; 1997 Dec; 11(6):558-64. PubMed ID: 9408684
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of antibodies to non-HLA antigens in organ transplantation.
Moraes JR; Luo Y; Moraes ME; Stastny P
Clin Lab Med; 1991 Sep; 11(3):621-32. PubMed ID: 1934967
[TBL] [Abstract][Full Text] [Related]
14. Donor-specific HLA antibodies after transplantation are associated with deterioration in cardiac function.
Leech SH; Mather PJ; Eisen HJ; Pina IL; Margulies KB; Bove AA; Jeevanandam V
Clin Transplant; 1996 Dec; 10(6 Pt 2):639-45. PubMed ID: 8996758
[TBL] [Abstract][Full Text] [Related]
15. The changing role of antibody testing in transplantation.
Leffell MS; Montgomery RA; Zachary AA
Clin Transpl; 2005; ():259-71. PubMed ID: 17424745
[TBL] [Abstract][Full Text] [Related]
16. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
[TBL] [Abstract][Full Text] [Related]
17. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients.
George JF; Kirklin JK; Shroyer TW; Naftel DC; Bourge RC; McGiffin DC; White-Williams C; Noreuil T
J Heart Lung Transplant; 1995; 14(5):856-64. PubMed ID: 8800720
[TBL] [Abstract][Full Text] [Related]
18. Crossmatching with B and T cells and flow cytometry.
Iwaki Y; Lau M; Cook DJ; Takemoto S; Terasaki PI
Clin Transpl; 1986; ():277-84. PubMed ID: 3154417
[TBL] [Abstract][Full Text] [Related]
19. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin.
Lobo PI; Spencer CE; Stevenson WC; Pruett TL
Transplantation; 1995 Feb; 59(3):357-60. PubMed ID: 7871565
[TBL] [Abstract][Full Text] [Related]
20. Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study.
Opelz G; Döhler B; Süsal C
Hum Immunol; 2009 Aug; 70(8):627-30. PubMed ID: 19375469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
